Overexpression of adenovirus-encoded transgenes from the cytomegalovirus immediate early promoter in irradiated tumor cells

Hum Gene Ther. 1997 Nov 20;8(17):2117-24. doi: 10.1089/hum.1997.8.17-2117.


Efficient expression of therapeutic genes in irradiated tumor cells would facilitate the conversion of a malignant tumor nodule into a cancer vaccine in situ. We reported previously that transgene expression from an adenoviral vector could be markedly enhanced by treating transduced tumor cells with butyrate. In this study, we demonstrated that a similar butyrate effect could be achieved in irradiated tumor cells. In addition, irradiating cells at doses of 2-40 Gy prior to transduction could also amplify recombinant adenoviral transgene products in a cell-type-specific manner. This suggests that adenovirus-mediated gene therapy, radiation therapy, and butyrate-mediated cancer therapy may potentially be formulated into one synergistic protocol for cancer treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenoviridae / genetics*
  • Animals
  • Antigens, Viral / genetics
  • Cytomegalovirus / genetics
  • Feasibility Studies
  • Gene Expression*
  • Genes, Reporter
  • Genetic Therapy
  • Genetic Vectors*
  • Humans
  • Immediate-Early Proteins / genetics
  • Luciferases / genetics
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Neoplasms / therapy
  • Promoter Regions, Genetic*
  • Transgenes*
  • Tumor Cells, Cultured


  • Antigens, Viral
  • Immediate-Early Proteins
  • immediate-early proteins, cytomegalovirus
  • Luciferases